Technical Analysis for AGE - AgeX Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 3.93 2.61% 0.10
AGE closed up 2.61 percent on Monday, June 24, 2019, on approximately normal volume. It was able to find support at its 50 day moving average. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Up
See historical AGE trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
50 DMA Support Bullish 2.61%
MACD Bullish Centerline Cross Bullish 2.61%
Upper Bollinger Band Walk Strength 2.61%
Wide Bands Range Expansion 2.61%
Overbought Stochastic Strength 2.61%

Older signals for AGE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
AgeX is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte™ technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology. Renelon™ is a first-generation iTR product designed to promote scarless tissue repair which AgeX plans to initially develop as a topically-administered device for commercial development through a 510(k) application. In addition to the product candidates in early development, AgeX, through its LifeMap subsidiary, currently markets genomic interpretation algorithms. AgeX also markets Cytiva® comprised of PSC-derived heart muscle cells used in screening drugs for efficacy and safety.
Biotechnology Life Sciences Biology Diseases Stem Cells Cell Biology Tissue Engineering Degenerative Disease Cloning Stem Cell Telomerase
Is AGE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.95
52 Week Low 1.13
Average Volume 77,849
200-Day Moving Average 0.0
50-Day Moving Average 3.7704
20-Day Moving Average 3.064
10-Day Moving Average 3.355
Average True Range 0.2717
ADX 30.05
+DI 32.4646
-DI 14.7084
Chandelier Exit (Long, 3 ATRs ) 3.1849
Chandelier Exit (Short, 3 ATRs ) 3.3651
Upper Bollinger Band 3.9828
Lower Bollinger Band 2.1452
Percent B (%b) 0.97
BandWidth 59.97389
MACD Line 0.054
MACD Signal Line -0.1342
MACD Histogram 0.1883
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.29
Resistance 3 (R3) 4.27 4.12 4.23
Resistance 2 (R2) 4.12 4.03 4.14 4.21
Resistance 1 (R1) 4.03 3.98 4.08 4.05 4.19
Pivot Point 3.88 3.88 3.91 3.90 3.88
Support 1 (S1) 3.79 3.79 3.84 3.81 3.67
Support 2 (S2) 3.64 3.74 3.66 3.65
Support 3 (S3) 3.55 3.64 3.63
Support 4 (S4) 3.57